News Search

Tag: Gene therapy program

Penn Gene-Editing Spinout iEcure Receives Rare Pediatric Disease Designation from FDA for Lead Drug Candidate

iEcure is developing the new drug candidate, GTP-506, as a treatment for a rare genetic condition caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia.

Penn Spinout REGENXBIO Inc. Enters Commercial Phase; Focuses Gene Therapy on Common Cause of Blindness

Regenxbio's gene therapy would eliminate the need for wet AMD patients to visit their doctor every few months to receive a needle in their eye to treat their condition.

Penn Spinout Regenxbio Opens New Gene Therapy Manufacturing Facility in Maryland

Regenxbio, a gene therapy company founded through collaboration with PCI, opened a new facility at its Maryland campus.

The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies

Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics

G2Bio launches with $200M to invest in research and development of novel gene therapies

The G2 Bio Companies, founded by James M. Wilson and the late Tachi Yamada, launched with a $200 million investment commitment from the global investment firm Temasek.

Penn’s gene therapy program has signed a 150,000 sq ft lease at a former GlaxoSmithKline property in King of Prussia

“The Penn transaction is an indicator that the entire region is benefiting from the research being done in our world-renowned institutions.”


Skip to content